Swedish immunology company InDex Pharmaceuticals InDex Pharmaceuticals has signed a license agreement with the Japanese subsidiary of Viatris to register and commercialize cobitolimod in Japan for the treatment of ulcerative colitis. 1 June 2023
Shares of US biotech Amylyx Pharmaceuticals fell more than 3% by close of trading Tuesday and a further 2.2% to $23.51 in pre-market activity today, after it said that a European regulatory panel had taken a negative view on its amyotrophic lateral sclerosis (ALS) treatment 31 May 2023
Swiss biotech Idorsia today revealed that Simon Jose will leave his position as chief commercial officer and member of the Idorsia executive committee to pursue other opportunities. 30 May 2023
Privately-held Italian drugmaker Menarini has announced results from a new analysis of the pivotal EMERALD clinical study that suggest that oral single-agent Orserdu (elacestrant) may be effective in ER+, HER2- advanced or metastatic breast cancer patients with non-detected ESR1-mut whose disease has progressed within six months of treatment with a CDK4/6i. 30 May 2023
US biopharma Apellis Pharmaceuticals and Swedish Orphan Biovitrum, also known as Sobi, have become the latest to discover the difficulty of drug development in amyotrophic lateral sclerosis (ALS). 26 May 2023
PTC Therapeutics’ stock plummeted 19.6%, ending the regular session at $46.95, after it revealed top-line results from the MOVE-FA Phase III trial of vatiquinone in patients with Friedreich ataxia. 25 May 2023
Shares of US oncology drugmaker Mirati Therapeutics closed down 4% on Wednesday and were a further 8.7% lower at $40.01 in pre-market activity today, after it revealed that the SAPPHIRE study did not meet its primary endpoint of overall survival (OS) at the final analysis. 25 May 2023
Boston, USA-based cell and gene therapy incubator ElevateBio has raised $401 million in a series D financing round led by AyurMaya Capital Management Fund. 24 May 2023
UK headquartered Biodexa Pharmaceuticals, a company developing treatments for metastatic brain cancers, has signed non-binding letter of intent to potentially acquire Varian Biopharmaceuticals, a private US precision oncology company developing novel therapeutics for the treatment of cancer. 24 May 2023
As part of its growth strategy, UK biotech Fixed Phage, a developer of proprietary, anti-infective technologies, today announced the appointment Dr Neil Clelland as its new chief executive (CEO). 24 May 2023
Adding to previous collaborations between the companies, Icelandic biosimilars company Alvotech and privately-held UK firm Advanz Pharma have entered into an exclusive partnership agreement regarding the supply and commercialization of five biosimilar candidates in Europe. 24 May 2023
Shares of Belgian biotech BioSenic were up more than 11% at 0.13 euros today, after it announced the signing of a term sheet with Pluristyx, a leading provider of gene-edited iPSC and cell therapy solutions, with a view to further negotiate the terms and conditions of a potential license and collaboration agreement. 24 May 2023
Following a positive advisory committee vote last month, the US Food and Drug Administration (FDA) yesterday approved Xacduro (sulbactam for injection; durlobactam for injection), developed by Entasis Therapeutics, a subsidiary of Innoviva. 24 May 2023
US RNA medicines company Wave Life Sciences saw its shares close up 2.7% at $3.81 yesterday, despite announcing that it is discontinuing an important program. 24 May 2023
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024